What Eli Lilly (NYSE: LLY) is doing is far more impressive. While many investors may buy it for its growth potential, here's ...

(This Dec. 17 story has been corrected to say that the EU regulator reversed its July decision in November to recommend ...

Eli Lilly (NYSE:LLY) announced Wednesday that China's National Medical Products Administration (NMPA) has approved its ...

Eli Lilly's key products, Mounjaro and Zepbound, dominate the U.S. weight loss market. Read more to see why I rate LLY stock ...

Pharmaceutical giant Eli Lilly (NYSE: LLY) is having a moment right now. Over the last two years the company has made a ...

Eli Lilly & Co.’s weight-loss and diabetes drug Mounjaro won’t be reclassified as a sleep apnea treatment in Europe, with ...

Eli Lilly, the pharma giant behind the popular weight-loss drug Zepbound, said it plans to test obesity medications as a ...

The European Medicines Agency has allowed Eli Lilly to update the product label of its weight-loss drug Mounjaro to show it ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 488.46% and ...

The Village of Pleasant Prairie Plan Commission on Monday approved the preliminary site and operational plans for the ...

On the other hand, the nature of its industry means that there will often be solid new reasons to be a bit more cautious ...

The summary highlights significant activities in the health sector, including Eli Lilly's Alzheimer's treatment approval in ...